MedTrace Logo

A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults

NCT06475846 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2025-01-20

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of HRS5580 for preventing of postoperative nausea and vomiting in adults. To explore the reasonable dosage of HRS5580 for postoperative nausea and vomiting.

Conditions

  • Preventing of Postoperative Nausea and Vomiting in Adults

Interventions

DRUG

HRS5580

HRS5580; low dose

DRUG

HRS5580

HRS5580; middle dose

DRUG

HRS5580

HRS5580; middle dose

DRUG

Ondansetron

Ondansetron

DRUG

blank preparation

blank preparation.

Sponsors & Collaborators

  • Fujian Shengdi Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2024-10-29
Completion
2024-10-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06475846 on ClinicalTrials.gov